Point un­veils new In­dy site to shore up sup­ply chain in fight against prostate can­cer

With a new man­u­fac­tur­ing fa­cil­i­ty and a can­di­date for prostate can­cer in clin­i­cal tri­als, Point Bio­phar­ma is mov­ing fast to bring its ra­di­oli­gand op­er­a­tions on­line. Now, it will get some help from the US De­part­ment of En­er­gy.

Point will re­ceive ac­tini­um-225 from the DOE’s Iso­tope Pro­gram to sup­port its ear­ly-stage pipeline and in-house man­u­fac­tur­ing of lutetium-177, a ra­dioac­tive med­i­cine that binds it­self to tu­mor cells. The help will al­low Point to stay on track to launch in 2023 and will sup­ple­ment the com­pa­ny’s sup­ply chain from Ter­raPow­er, North­Star Med­ical and Ionetix. All of these part­ner­ships will help bol­ster the com­pa­ny’s in­ter­nal pro­duc­tion, the com­pa­ny said.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN